Patients Ulcerative colitis

0 replies


Topic of the discussion

Member Carenity • Community manager
Posted on

Hello Carenity members,

Yesterday the FDA approved a new medicine for Ulcerative Colitis. 

The medication is called Xeljanz (tofacitinib) and is for adults with moderately to severely active ulcerative colitis. "Xeljanz is the first oral medication approved for chronic use in this indication."

"The efficacy of Xeljanz for the treatment of moderately to severely active ulcerative colitis was demonstrated in three controlled clinical trials. This included two 8-week placebo-controlled trials that demonstrated that 10 mg of Xeljanz given twice daily induces remission in 17 to 18 percent of patients by week eight. In a placebo-controlled trial among patients who achieved a clinical response by week eight, Xeljanz, at a 5 mg or 10 mg dose given twice daily, was effective in inducing remission by week 52 in 34 percent and 41 percent of patients, respectively. Among patients who achieved remission after 8 weeks of treatment, 35 percent and 47 percent achieved sustained corticosteroid-free remission when treated with 5 mg and 10 mg, respectively."

Please feel free to comment on your thoughts.

Full article available here: